INC Research Holdings (NASDAQ: INCR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for INC Research Holdings and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INC Research Holdings 0 4 4 0 2.50
ACADIA Pharmaceuticals 0 3 9 0 2.75

INC Research Holdings presently has a consensus target price of $64.58, suggesting a potential upside of 23.49%. ACADIA Pharmaceuticals has a consensus target price of $44.17, suggesting a potential upside of 19.86%. Given INC Research Holdings’ higher possible upside, equities research analysts plainly believe INC Research Holdings is more favorable than ACADIA Pharmaceuticals.

Volatility and Risk

INC Research Holdings has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 3.9, suggesting that its share price is 290% more volatile than the S&P 500.

Institutional and Insider Ownership

99.0% of INC Research Holdings shares are owned by institutional investors. Comparatively, 97.1% of ACADIA Pharmaceuticals shares are owned by institutional investors. 0.2% of INC Research Holdings shares are owned by insiders. Comparatively, 22.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares INC Research Holdings and ACADIA Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
INC Research Holdings 5.69% 40.69% 9.87%
ACADIA Pharmaceuticals -485.14% -62.08% -57.18%

Valuation and Earnings

This table compares INC Research Holdings and ACADIA Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
INC Research Holdings $1.03 billion 5.26 $226.74 million $1.61 32.48
ACADIA Pharmaceuticals $62.99 million 71.61 -$305.32 million ($2.53) -14.57

INC Research Holdings has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than INC Research Holdings, indicating that it is currently the more affordable of the two stocks.

Summary

INC Research Holdings beats ACADIA Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

INC Research Holdings Company Profile

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.